Menu
Celebrating 33 Years of Cancer Breakthroughs
Every person fighting cancer deserves access to the most innovative treatments available. That’s a promise Gateway has championed since 1991. Here are the milestones in our journey:
- Overall cancer death rate decreased by 34%
- Numerous clinical trials funded leading to innovative treatments
- Continued focus on under-researched cancer types
The overall cancer death rate for men, women and children has decreased by 34% since its peak in 1991, the same year Gateway for Cancer Research was established.
Blood Cancer
Driving advancements in treatment and survival rates.
Death Rate Reduction
Since 1991, deaths from blood cancer have decreased by 35%.
Innovative Clinical Trials
Approximately 25% of Gateway-funded trials focus on blood cancer.
Survival Rate Increase
5-year survival rate for blood cancers has increased by 40%.
Pioneering Treatments
First known study of venetoclax in children with relapsed AML.
A Gateway-funded clinical trial marked the first study to use a targeted therapy for the prevention of myeloid neoplasms.
Brain Cancer
Investing in promising research and new therapies.
Death Rate Reduction
Deaths attributed to brain cancer have decreased by 12.5% since 1991.
Increased Survival Rate
5-year survival rate has seen a 10% increase.
Funding Milestone
Nearly $15 million invested in brain cancer clinical trials.
Innovative Imaging Drug
Promising trial for first FDA-approved imaging drug for pediatric brain tumors.
Breast Cancer
Leading the way in breast cancer research and treatments.
Death Rate Reduction
Breast cancer deaths have decreased by 42.7% since 1991
High Incidence
Expected to have the highest incidence rate in 2024
Clinical Trials Focus
13% of Gateway-funded trials focus on breast cancer.
HER2-Positive Study
Funded trial for older patients with HER2-positive breast cancer.
Colorectal Cancer
Discovering new ways to improve patient outcomes.
Death Rate Reduction
Colorectal cancer deaths have dropped by 47.4% since 1991.
Second Deadliest
Expected to be the second deadliest cancer type in 2024.
Clinical Trials Focus
5% of Gateway-funded trials center on colorectal cancer.
Novel Drug Combination
Funding pilot study of a novel drug combination for ctDNA positive patients.
Lung Cancer
Pushing boundaries for breakthroughs in treatment and survival.
Leading Cause of Death
Despite being the leading cause of cancer death. Lung cancer deaths have dropped by nearly 50% since 1991.
Increased Survival Rate
96.3% increase in 5-year survival rate since 1991.
Personalized Vaccine Study
Gateway-funded clinical trial is the only known ongoing study of a personalized vaccine used in first-line therapy for small cell lung cancer.
Pancreas Cancer
Focusing on one of the deadliest cancers.
Increased Survival Rate
198% increase in 5-year survival rate since 1991.
Research Investment
Gateway has invested approximately $6.6 million in pancreas cancer research since 1991.
Potential Breakthrough
Gateway is funding the investigation of a targeted therapy, ivosidenib, for pancreatic cancer and should the trial be successful it would mark the first targeted therapy approved for pancreatic cancer.
Prostate Cancer
Transforming lives – improving outcomes for men.
Second Highest Incidence
Prostate cancer, which has the second highest incidence and is the second leading cause of cancer death in men, has seen an incredible 52% drop in deaths since 1991.
Research Investment
Gateway for Cancer Research has invested more than $6.7 million in the same 30-year period in clinical trials seeking to improve health outcomes for prostate cancer.
